HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.

Article Details

Citation
Copy to clipboard

Bello-Rivero I, Garcia-Vega Y, Duncan-Roberts Y, Vazquez-Blomquistc D, Santana-Milian H, Besada-Perez V, Rios-Cabrera M

HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.

Semin Oncol. 2018 Jan;45(1-2):27-33. doi: 10.1053/j.seminoncol.2018.04.007. Epub 2018 May 4.

PubMed ID
30318081 [ View in PubMed
]
Abstract

The rational combination of recombinant IFN-alpha2b and IFN-gamma resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile.

DrugBank Data that Cites this Article

Drugs